SMT201500122B - Composto di triazolopiridina e sua azione come inibitore di prolilidrossilasi e induttore della produzione di eritropoientina - Google Patents

Composto di triazolopiridina e sua azione come inibitore di prolilidrossilasi e induttore della produzione di eritropoientina

Info

Publication number
SMT201500122B
SMT201500122B SM201500122T SM201500122T SMT201500122B SM T201500122 B SMT201500122 B SM T201500122B SM 201500122 T SM201500122 T SM 201500122T SM 201500122 T SM201500122 T SM 201500122T SM T201500122 B SMT201500122 B SM T201500122B
Authority
SM
San Marino
Prior art keywords
erythropoientine
prolylhydroxylase
inducer
inhibitor
action
Prior art date
Application number
SM201500122T
Other languages
English (en)
Italian (it)
Inventor
Ikuo Mitani
Yosuke Ogoshi
Takuya Matsui
Masahiro Yokota
Masakazu Terashita
Dai Motoda
Kazuhito Ueyama
Hiroyuki Abe
Takahiro Hotta
Takashi Ito
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of SMT201500122B publication Critical patent/SMT201500122B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
SM201500122T 2009-07-17 2015-05-22 Composto di triazolopiridina e sua azione come inibitore di prolilidrossilasi e induttore della produzione di eritropoientina SMT201500122B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009169565 2009-07-17
US27312709P 2009-07-30 2009-07-30
PCT/JP2010/062037 WO2011007856A1 (ja) 2009-07-17 2010-07-16 トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用

Publications (1)

Publication Number Publication Date
SMT201500122B true SMT201500122B (it) 2015-07-09

Family

ID=43449466

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500122T SMT201500122B (it) 2009-07-17 2015-05-22 Composto di triazolopiridina e sua azione come inibitore di prolilidrossilasi e induttore della produzione di eritropoientina

Country Status (29)

Country Link
US (3) US8283465B2 (ru)
EP (3) EP3594213A1 (ru)
JP (8) JP5021797B2 (ru)
KR (4) KR20180042443A (ru)
CN (1) CN102471337B (ru)
AR (1) AR077417A1 (ru)
AU (1) AU2010271732B2 (ru)
BR (1) BR112012001157A2 (ru)
CA (1) CA2768505C (ru)
CO (1) CO6430426A2 (ru)
DK (1) DK2455381T5 (ru)
ES (1) ES2477968T3 (ru)
HK (1) HK1168346A1 (ru)
HR (1) HRP20140705T1 (ru)
IL (1) IL217541A (ru)
ME (1) ME01858B (ru)
MX (1) MX2012000766A (ru)
MY (1) MY160814A (ru)
NZ (1) NZ598242A (ru)
PE (1) PE20120629A1 (ru)
PL (1) PL2455381T3 (ru)
PT (1) PT2455381E (ru)
RS (1) RS53499B1 (ru)
RU (1) RU2538963C2 (ru)
SG (1) SG178049A1 (ru)
SI (1) SI2455381T1 (ru)
SM (1) SMT201500122B (ru)
TW (1) TWI485150B (ru)
WO (1) WO2011007856A1 (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2455381T3 (pl) * 2009-07-17 2014-10-31 Japan Tobacco Inc Triazolopirydynowy związek i jego działanie jako inhibitora hydroksylazy prolinowej i środka indukującego wytwarzanie erytropoetyny
JP2011168582A (ja) * 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
WO2014080640A1 (ja) 2012-11-26 2014-05-30 国立大学法人東北大学 エリスロポエチン発現増強剤
NZ708605A (en) 2012-12-24 2016-07-29 Cadila Healthcare Ltd Novel quinolone derivatives
US11857543B2 (en) 2013-06-13 2024-01-02 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
RU2534804C1 (ru) * 2013-08-05 2014-12-10 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ, ПРОЯВЛЯЮЩИЕ СВОЙСТВА АНТАГОНИСТОВ АДЕНОЗИНОВЫХ А2А РЕЦЕПТОРОВ, И ИХ ПРИМЕНЕНИЕ
SI3052096T1 (en) * 2013-10-03 2018-04-30 Kura Oncology, Inc. EAQ inhibitors and application procedures
AU2015311333B2 (en) 2014-09-02 2017-11-16 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof
JP2018039733A (ja) * 2014-12-22 2018-03-15 株式会社富士薬品 新規複素環誘導体
GB201504565D0 (en) * 2015-03-18 2015-05-06 Takeda Pharmaceutical Novel compounds
CN106146395B (zh) * 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
KR102473897B1 (ko) 2015-05-28 2022-12-06 니뽄 다바코 산교 가부시키가이샤 당뇨병성 신증을 치료 또는 예방하는 방법
EP3546459A4 (en) * 2016-11-25 2020-05-20 Japan Tobacco, Inc. METHOD FOR PRODUCING A TRIAZOLOPYRIDINE COMPOUND
JP7142406B2 (ja) * 2017-05-09 2022-09-27 カインド ファーマシューティカル インドリジン誘導体及びその医学的応用
CN111148735B (zh) * 2017-10-04 2023-08-08 日本烟草产业株式会社 含氮杂芳基化合物及其药物用途
CN107739378A (zh) * 2017-11-14 2018-02-27 杭州安道药业有限公司 吲哚嗪衍生物及其在医药上的应用
EP3808747A4 (en) * 2018-09-13 2022-03-09 Kissei Pharmaceutical Co., Ltd. IMIDAZOPYRIDINONE COMPOUND
CN110105355B (zh) * 2019-05-24 2021-09-21 烟台大学 一种1,2,3-三唑-[1,5-a]并喹啉类化合物的制备方法
AU2021233433A1 (en) * 2020-03-11 2022-10-06 Kissei Pharmaceutical Co., Ltd. Crystal of imidazopyridinone compound or salt thereof
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
CN113387948B (zh) * 2021-02-06 2022-06-10 成都诺和晟泰生物科技有限公司 一种稠环杂芳基衍生物及其药物组合物和治疗方法及用途
WO2022251563A1 (en) 2021-05-27 2022-12-01 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
CN113582843A (zh) * 2021-09-09 2021-11-02 无锡捷化医药科技有限公司 一种5-氯-2-氟-3-羟基苯甲酸乙酯的制备方法
CN114031619A (zh) * 2021-12-17 2022-02-11 山东汇海医药化工有限公司 一种图卡替尼中间体的制备方法
WO2024061172A1 (zh) * 2022-09-19 2024-03-28 苏中药业集团股份有限公司 一种脯氨酰羟化酶抑制剂及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19746287A1 (de) * 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6355653B1 (en) * 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
MXPA04003277A (es) * 2001-10-08 2004-07-23 Hoffmann La Roche Amida del acido 8-amino-?1,2,4?triazolo?1,5-a?piridina-6-carboxilico.
JP2007501844A (ja) 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
RU2007106180A (ru) * 2004-08-05 2008-09-10 Ф. Хоффманн-Ля Рош Аг (Ch) Производные индола, индазола или индолина
FR2889383A1 (fr) * 2005-08-01 2007-02-02 France Telecom Procede et dispositif de detection pour systeme mimo, systeme mimo, programme et support d'information
TW200808793A (en) * 2006-03-07 2008-02-16 Smithkline Beecham Corp Prolyl hydroxylase inhibitors
WO2007136990A2 (en) 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
TWI394747B (zh) * 2006-06-23 2013-05-01 Smithkline Beecham Corp 脯胺醯基羥化酶抑制劑
DK3357911T3 (da) * 2006-06-26 2022-07-04 Akebia Therapeutics Inc Prolylhydroxylaseinhibitorer og fremgangsmåder til anvendelse
WO2008006540A1 (en) 2006-07-12 2008-01-17 Syngenta Participations Ag Triazolopyridine derivatives as herbicides
TW200845991A (en) * 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
ES2442847T3 (es) 2007-04-18 2014-02-13 Amgen, Inc Quinolonas y azaquinolonas que inhiben la prolil hidroxilasa
AU2008248165B2 (en) 2007-05-04 2011-12-08 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
US20110028463A1 (en) 2007-07-03 2011-02-03 Astellas Pharma Inc. Amide compounds
US20100305154A1 (en) * 2007-11-30 2010-12-02 Glaxosmithkline Llc Prolyl Hydroxylase Inhibitors
EP2227770A4 (en) * 2007-11-30 2011-11-09 Glaxosmithkline Llc PROLYLHYDROXYLASEINHIBITOREN
WO2009126624A1 (en) * 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolo compounds useful as dgat1 inhibitors
JP2011519858A (ja) 2008-04-30 2011-07-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラ−ゼ阻害剤
US20110077248A1 (en) 2008-05-29 2011-03-31 Sirtris Pharmaceuticals, Inc. Imidazopyridine and related analogs as sirtuin modulators
AU2009328752B2 (en) 2008-12-19 2015-07-16 Leo Pharma A/S Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases
PL2455381T3 (pl) * 2009-07-17 2014-10-31 Japan Tobacco Inc Triazolopirydynowy związek i jego działanie jako inhibitora hydroksylazy prolinowej i środka indukującego wytwarzanie erytropoetyny

Also Published As

Publication number Publication date
KR101850661B1 (ko) 2018-04-19
KR101706803B1 (ko) 2017-02-14
JP2012144571A (ja) 2012-08-02
MX2012000766A (es) 2012-02-08
JP2020111612A (ja) 2020-07-27
DK2455381T5 (en) 2015-02-09
JP2017214404A (ja) 2017-12-07
ES2477968T3 (es) 2014-07-18
IL217541A0 (en) 2012-02-29
EP2455381A4 (en) 2012-12-12
ME01858B (me) 2014-12-20
BR112012001157A2 (pt) 2016-02-23
DK2455381T3 (da) 2014-07-21
RU2538963C2 (ru) 2015-01-10
EP2455381B9 (en) 2014-10-22
US20160145254A1 (en) 2016-05-26
MY160814A (en) 2017-03-31
KR20230165366A (ko) 2023-12-05
PL2455381T3 (pl) 2014-10-31
AU2010271732B2 (en) 2016-08-25
CO6430426A2 (es) 2012-04-30
JP2015003933A (ja) 2015-01-08
RS53499B1 (en) 2015-02-27
KR20180042443A (ko) 2018-04-25
KR20170018105A (ko) 2017-02-15
NZ598242A (en) 2013-09-27
EP2455381A1 (en) 2012-05-23
TW201105671A (en) 2011-02-16
JP2019019144A (ja) 2019-02-07
JP6434575B2 (ja) 2018-12-05
TWI485150B (zh) 2015-05-21
EP2455381B1 (en) 2014-05-28
SI2455381T1 (sl) 2014-08-29
KR20120051704A (ko) 2012-05-22
RU2012105467A (ru) 2013-08-27
CA2768505C (en) 2018-06-12
EP2746282A1 (en) 2014-06-25
AR077417A1 (es) 2011-08-24
PE20120629A1 (es) 2012-05-30
US20110077267A1 (en) 2011-03-31
IL217541A (en) 2014-07-31
PT2455381E (pt) 2014-06-24
HRP20140705T1 (hr) 2014-09-12
US20130096155A1 (en) 2013-04-18
WO2011007856A1 (ja) 2011-01-20
SG178049A1 (en) 2012-03-29
JP5021797B2 (ja) 2012-09-12
AU2010271732A1 (en) 2012-03-08
JP2022126843A (ja) 2022-08-30
HK1168346A1 (en) 2012-12-28
EP3594213A1 (en) 2020-01-15
CN102471337B (zh) 2014-12-10
JP2016040321A (ja) 2016-03-24
ES2477968T9 (es) 2014-11-13
US8283465B2 (en) 2012-10-09
JP2011037841A (ja) 2011-02-24
CN102471337A (zh) 2012-05-23
CA2768505A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
SMT201500122B (it) Composto di triazolopiridina e sua azione come inibitore di prolilidrossilasi e induttore della produzione di eritropoientina
SMT201600021B (it) Nuovi composti di chinolina sostituiti come inibitori della s-nitrosoglutatione reduttasi
SMT201600135B (it) Nuovi inibitori della s-nitrosoglutatione riduttasi
SMT201600291B (it) Inibitori di proteasi hcv
SMT201700036B (it) Composti e composizioni come inibitori di protein chinasi
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
SMT201500262B (it) Trattamento della sclerosi multipla con laquinimod
SMT201500043B (it) Indazoli ossazolo-sostituiti come inibitori di pi13-chinasi
SMT201500271B (it) Inibitori di neprilisina
BR112012000934A2 (pt) cassetes e métodos de utilizacao destes
DK2504332T4 (da) Amorf form og krystallinsk form af genz 112638-hemitartrat som inhibitor af glucosylceramidsyntase
SMT201400169B (it) Nuovo composto utile per il trattamento di malattie degenerative e infiammantorie
BR112012008483A2 (pt) combunações de um inibidor de pi3k e um inibidor de mex
BRPI1010884A2 (pt) composto inibidores hdac de alcanoilamino benzamida anilina
SMT201500268B (it) Derivato di 5-idrossipirimidin-4-carbossammide
HK1215186A1 (zh) 炎症性疾病的抑制劑
SMT201500156B (it) Composti di diidropirrolonaftiridinione come inibitori di jak
SMT201500071B (it) Agenti antimalarici che sono inibitori della diidro-orotato deidrogenasi
BRPI1011267A2 (pt) inibidores de protease
SI2506840T1 (sl) Uporabe zaviralcev faktorja, ki jih inducira hiposkija
IT1400092B1 (it) Metodo di crioconservazione di polpa dentale
IT1398549B1 (it) Silil- derivati di polisaccaridi
IT1404249B1 (it) Parete di banchina e procedimento per la sua realizzazione
DK2331548T3 (da) Proteasehæmmere
SMT201300048B (it) Cocristalli di tramadol e inibitori della cox-2